Group 1 - The core viewpoint of the report indicates that CSPC Pharmaceutical Group's revenue for the first half of the year decreased by 35% year-on-year to HKD 2.147 billion, primarily due to a decline in sales volume of intravenous (IV) infusions and ampoule injections [1] - Net profit fell by 59% to HKD 284 million, reflecting the challenging market conditions [1] - In the 11th round of drug centralized procurement (GPO), CSPC has 11 drugs, including bromhexine, which are expected to account for approximately 1.5% of sales in 2024, with a significant opportunity to win peritoneal dialysis fluid contracts and renew other products [1] Group 2 - Citigroup has revised its revenue forecasts for CSPC for the fiscal years 2025 to 2027 down by 21%, 20%, and 21% respectively, and lowered earnings per share forecasts by 38% to reflect the latest sales trends and lower gross margins due to price declines [1] - The target price for CSPC has been reduced from HKD 7 to HKD 5, while maintaining a "buy" rating, as the company is viewed as a winner among generic drug firms and the largest beneficiary of drug GPOs [1]

Group 1 - The latest shareholder equity disclosure for Stone Four Pharmaceutical Group (02005) and Huaxin Cement (06655) was conducted on September 5, 2025 [1] - China Pharmaceutical Company Limited increased its holdings in Stone Four Pharmaceutical Group from 878 million shares to 879 million shares, representing a holding percentage change from 29.74% to 29.77% [2] - Qu Jiguang increased his holdings in Stone Four Pharmaceutical Group from 1.169 billion shares to 1.170 billion shares, with a holding percentage change from 39.61% to 39.64% [2] Group 2 - Liu Weisheng acquired 20,000 shares in Huaxin Cement, changing his holding from 0 shares to 20,000 shares, resulting in a holding percentage of 0% [2]

格隆汇9月5日丨根据联交所最新权益披露资料显示，2025年9月4日，石四药集团(02005.HK)获执行董事兼主席兼行政总裁曲继广在场内以每股均2.9652港元 增持88万股，涉资约260.94万港元。 | 股份代號: | 02005 | | --- | --- | | 上市法國名稱: | 石四藥集團有限公司 | | 日期 (日 / 月 / 年): | 05/08/2025 - 05/09/202 | | 表格序號 | | 大股東/董事/最高行政人員名 作出披露的 買入 / 費出或涉及的 每股的平均價 | | | | | 持有權益的股份數目 佔已發行的 有關事件的日期 相 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 鳥内 | 股份數目 | | | (語參閱 述*語 | 有投票權股(日/月/年) 權 | | | | | | | | | 份自分比 | | | | | | | | | ( %) | | CS20250904E00161 | China Pharmaceutical | 1710(L) | | 880.000(L) | HKD 2 ...

Group 1 - The company, Shijiazhuang Fourth Pharmaceutical Group, announced on September 1 that it has obtained the drug production registration certificate from the National Medical Products Administration for Allopurinol Tablets (0.1g), classified as a Class 3 chemical drug, which is considered to have passed the consistency evaluation [2] - Allopurinol Tablets are primarily used for the treatment of primary or secondary gout patients, patients undergoing treatment for leukemia, lymphoma, and malignant tumors, as well as for the treatment of recurrent calcium oxalate stone patients [2]

Core Viewpoint - The company, Stone Four Pharmaceutical Group, has obtained the drug production registration approval from the National Medical Products Administration of China for Allopurinol Tablets (0.1g), classified as a Class 3 chemical drug, which is considered equivalent to passing the consistency evaluation [1] Group 1 - Allopurinol Tablets are primarily used for the treatment of patients with primary or secondary gout, leukemia, lymphoma, and malignant tumors, as well as for patients with recurrent calcium oxalate stones [1]

Core Viewpoint - The company has obtained the drug production registration approval for Allopurinol Tablets (0.1g) from the National Medical Products Administration of China, which is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation [1] Group 1 - Allopurinol Tablets are primarily used for the treatment of patients with primary or secondary gout, leukemia, lymphoma, and malignant tumors, as well as for patients with recurrent calcium oxalate stones [1]

格隆汇9月1日丨石四药集团(02005.HK)公告，集团已取得中国国家药监局有关别嘌醇片(0.1g)的药品生 产注册批件，属于化学药品第3类，视同通过一致性评价。 别嘌醇片主要用于原发性或继发性痛风患者、接受治疗的白血病，淋巴瘤和恶性肿瘤患者、及用于对复 发性草酸钙结石患者的治疗。集团的别嘌醇原料药已获国家药监局批准登记成为在上市制剂使用的原料 药。 ...

公司名稱: 石四藥集團有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02005 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.02 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.02 | HKD | | 200,000,000 | 本月底法定/註 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團已取得中國國家藥品監督管理局（「國家藥監局」）有關別嘌醇片(0.1g)的藥品生產註冊 批件，屬於化學藥品第3類，視同通過一致性評價。 別嘌醇片主要用於原發性或繼發性痛風患者、接受治療的白血病，淋巴瘤和惡性腫瘤患者、及 用於對復發性草酸鈣結石患者的治療。誠如本公司日期為二零二五年四月二十八日之公告所載， 本集團的別嘌醇原料藥已獲國家藥監局批准登記成為在上市製劑使用的原料藥。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 自願公告 產品開發的最新進展 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二五年九月一日 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣 ...

Core Viewpoint - The company Shijiazhuang Fourth Pharmaceutical Group has received approval from the National Medical Products Administration to produce three new pharmaceutical products, marking significant advancements in its product offerings [1] Group 1: Product Approvals - The approved products include Urapidil sustained-release capsules (30mg), Nicardipine hydrochloride sodium chloride injection (200ml), and Clonidine hydrochloride injection (2ml) [1] - Urapidil sustained-release capsules and Nicardipine hydrochloride sodium chloride injection are the first of their kind to be approved in China, indicating a competitive edge in the market [1] - Clonidine hydrochloride injection is also considered to have passed the consistency evaluation, categorized as a Class 4 chemical drug [1]